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Abstract
Glucokinase Regulatory Protein (GCKR) plays a central role regulating both hepatic triglyceride and glucose metabolism.
Fatty acids are key metabolic regulators, which interact with genetic factors and influence glucose metabolism and other
metabolic traits. Omega-3 polyunsaturated fatty acids (n-3 PUFA) have been of considerable interest, due to their potential
to reduce metabolic syndrome (MetS) risk.
Objective: To examine whether genetic variability at the GCKR gene locus was associated with the degree of insulin
resistance, plasma concentrations of C-reactive protein (CRP) and n-3 PUFA in MetS subjects.
Design: Homeostasis model assessment of insulin resistance (HOMA-IR), HOMA-B, plasma concentrations of C-peptide, CRP,
fatty acid composition and the GCKR rs1260326-P446L polymorphism, were determined in a cross-sectional analysis of 379
subjects with MetS participating in the LIPGENE dietary cohort.
Results: Among subjects with n-3 PUFA levels below the population median, carriers of the common C/C genotype had
higher plasma concentrations of fasting insulin (P=0.019), C-peptide (P=0.004), HOMA-IR (P=0.008) and CRP (P=0.032) as
compared with subjects carrying the minor T-allele (Leu446). In contrast, homozygous C/C carriers with n-3 PUFA levels
above the median showed lower plasma concentrations of fasting insulin, peptide C, HOMA-IR and CRP, as compared with
individuals with the T-allele.
Conclusions: We have demonstrated a significant interaction between the GCKR rs1260326-P446L polymorphism and
plasma n-3 PUFA levels modulating insulin resistance and inflammatory markers in MetS subjects. Further studies are
needed to confirm this gene-diet interaction in the general population and whether targeted dietary recommendations can
prevent MetS in genetically susceptible individuals.
Trial Registration: ClinicalTrials.gov NCT00429195
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Introduction
The metabolic syndrome (MetS) represents a combination of
cardio-metabolic risk factors, including central obesity, insulin
resistance, hypertension, and dyslipidemia [1]. Low-grade inflam-
mation is characteristic of MetS and numerous studies have now
confirmed that plasma concentrations of C-reactive protein (CRP),
the most commonly measured biomarker of inflammation, are
elevated in individuals with MetS [2]. The expression of the MetS is
probably due to complex interactions between genetic and
environmental factors. Moreover, evidence suggest that some
people are genetically predisposed to insulin resistance [3], which
may represent an underlying mechanism for these metabolic
alterations. Among the environmental factors, diet may be the
most directly involved in the genetic modulation of the different
intermediate and final phenotypes of diabetes mellitus (T2DM) and
cardiovascular disease. Omega-3 polyunsaturated fatty acids (n-3
PUFA) are specially relevant, due to their potential ability to lower
risk of coronary heart disease and MetS [4,5,6]. However, limited
and inconsistent data are available concerning the relation between
n-3 PUFA and glucose metabolism. Furthermore, data from a
recent prospective study including 36,328 women in the Women’s
Health Study, suggest an increased risk of T2DM, especially with
higher intakes of n-3 PUFA [7]. This study supports the notion that
general recommendations may not be benefit equally to all
individuals underscoring the need to elucidate how certain dietary
components may modulate the risk conferred by genetic suscepti-
bility due to variation in genes involved in the etiology of MetS.
In the liver and pancreatic islet cells, glucokinase regulatory
protein (GCKR) modifies glucokinase, which functions as a
glucose sensor responsible for glucose phosphorylation in the first
step of glycolysis. In a murine experimental model, adenoviral-
mediated overexpression of GCKR in liver increased glucokinase
activity, which led to lowered blood glucose and increased
triglycerides concentrations [8]. Along these lines we have
provided evidence that common variation at the GCKR locus,
more specifically the functional rs1260326 (Pro446Leu) SNP, was
associated with opposite effects on fasting plasma triglycerides and
glucose concentrations in several populations [9]. Moreover Beer
et al. demonstrated that GCKR T-allele Pro446Leu has reduced
regulation by physiological concentrations of phosphate esters
fructose 6 (F6P), resulting indirectly in increased GCK activity
[10]. Altered GCK regulation in liver is predicted to enhance
glycolytic flux, promoting hepatic glucose metabolism and
elevating concentrations of malonyl-CoA, a substrate for de novo
lipogenesis, providing a mutational mechanism for the reported
association of this variant with raised triglycerides and lower
glucose levels [10]. Taken together, these data support the central
position of GCKR in pathways regulating hepatic triglyceride as
well as glucose metabolism in humans. In addition, we confirmed
recent findings that the same SNP is consistently associated with
CRP levels [9]. In view of the physiological role of GCKR in
glucose homeostasis and the link between insulin resistance,
inflammation and dietary fat, our primary aim was to examine
whether genetic variability at the GCKR gene locus in MetS
subjects might be associated with variability in insulin response
and CRP levels to n-3 PUFA. Moreover we also explored other
potential gene-nutrient interaction, such as saturated fatty acids
(SFA), monounsaturated fatty acids (MUFA) and n-6 PUFA.
Results
Baseline demographic and biochemical characteristics according
to the GCKR rs1260326-P446L polymorphism are presented in
Table 1. Genotype distributions did not deviate from Hardy-
Weinberg expectations. Given the low genotype frequencies of
individuals homozygous for the minor alleles, and because the
analysis did not suggest a recessive mode of inheritance, we
analyzed the rs1260326 SNP using two genotype categories. The
number of men and women enrolled in this study was 174 (55 C/C
and 119 C/T+T/T) and 205 (70 C/C and 135 C/T+T/T),
respectively. Consistent with previous studies, the variant GCKR T-
allele Pro446Leu (C/T+T/T) displayed higher plasma levels of
triglycerides and CRP but lower fasting glucose concentrations as
compared to homozygous Pro446 carriers (C/C) (Table 1). No
other significant baseline differences were observed in relation to
age, BMI, fasting plasma lipids, and insulin concentration by
genotype.
Given that the aim of this study was to investigate potential
gene-nutrient interactions, we examined the associated effect of
the GCKR rs1260326-P446L polymorphism on glucose metabo-
lism according to plasma fatty acid status. Gene-nutrient
interactions between the rs1260326 SNP and plasma level of n-3
PUFA were found. In the whole cohort, this SNP interacted with
plasma n-3 PUFA levels, which were significantly associated with
insulin resistance. Among subjects with n-3 PUFA levels below the
median (#3.68), the C/C genotype was associated with higher
fasting insulin concentrations (P=0.019), C-peptide (P=0.004)
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minor T-allele (Figure 1). In contrast, C/C homozygotes with n-3
PUFA levels above the median (.3.68) showed lower plasma
concentration of fasting insulin, C-peptide, and HOMA-IR,
compared with individuals carrying the T-allele (Figure 1).
HOMA-B did not differ between participants with different
genotypes. On the other hand we also measured the serum CRP
levels and the effect of the GCKR rs1260326-P446L polymorphism
according to plasma fatty acid status. With the highest level of n-3
PUFA, C/C subjects also showed lower CRP levels compared
with subjects carrying the T-allele (P=0.032) (Figure 1D). We
also examined the effect of this polymorphism on plasma
triglycerides concentrations, the main phenotype associated with
GCKR, and with plasma adiponectin levels. No significant
differences were observed for these both parameters related to
the plasma level of n-3 PUFA. Furthermore there were no
significant interactions between other groups of plasma fatty acids
(SFA, MUFA, n-6 PUFA, n-6/n-3 and the n-3/n-6 PUFA ratios),
and GCKR rs1260326-P446L polymorphism on glucose metab-
olism, triglycerides, CRP and adiponectin plasma levels.
Finally, a linear regression model including the original
covariates was applied to create predicted values of HOMA-IR
and CRP levels according to genotype at the rs1260326
polymorphism (Figure 2). The genotype groups exhibit striking
differences in the predicted changes in HOMA-IR and CRP in
relation to plasma n-3 PUFA concentrations. Thus, from baseline
data, the model predicts that in individuals carrying the minor T-
allele for rs1260326, an increase in plasma n-3 PUFA would elicit
a considerable raise in HOMA-IR and CRP levels. This increase
would not be seen in the major C-allele homozygote.
Discussion
Our findings support the hypothesis that the GCKR rs1260326-
P446L polymorphism influences insulin resistance by interacting
with plasma n-3 PUFA levels in MetS patients. Thus, among
subjects with low plasma n-3 PUFA levels, the C/C genotype
was associated with higher fasting insulin concentrations, C-
peptide levels and HOMA-IR compared to subjects carrying the
Figure 1. Interaction between the GCKR rs1260326-P446L polymorphism and plasma concentrations of omega-3 polyunsaturated
fatty acids (n-3 PUFA), above or below the median within the same genotype group of fasting insulin (A), C-peptide levels (B),
homeostasis model assessment of insulin resistance (HOMA-IR) (C) and C-reactive protein levels (CRP) (D). Values are means 6 SD. P
values were adjusted for age, sex, BMI, anti-hypertension pharmacological treatment and LIPGENE centre of origin.
doi:10.1371/journal.pone.0020555.g001
Table 1. Characteristics of participants at the baseline
according to the GCKR rs1260326-P446L polymorphism.
rs1260326
C/C C/T+T/T *P value
n 125 274
Age, years 55.02 (0.8) 53.91 (0.5) 0.259
BMI, kg/m2 32.59(0.4) 32.54 (0.2) 0.927
Total cholesterol, mmol/L 5.25 (0.07) 5.34 (0.06) 0.358
LDL-C, mmol/L 3.09 (0.10) 3.29 (0.06) 0.095
HDL-C, mmol/L 1.12 (0.01) 1.09 (0.01) 0.261
TG, mmol/L 1.62 (0.06) 1.84 (0.05) 0.016
ApoB, g/L 1.00 (0.01) 1.02 (0.01) 0.420
ApoA-1, g/L 1.39 (0.02) 1.4 (0.01) 0.657
Glucose (mmol/L) 6.09 (0.06) 5.87 (0.05) 0.012
Insulin (mU/L) 9.97 (0.52) 9.97 (0.33) 0.997
CRP (mg/L) 4.39 (0.31) 5.52 (0.28) 0.016
*P,0.05.
doi:10.1371/journal.pone.0020555.t001
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of plasma n-3 PUFA, showed lower fasting insulin concentra-
tions, C-peptide levels and HOMA-IR, compared to subjects
with the T-allele. Moreover, they also showed lower CRP levels.
These novel associations and gene-nutrient interactions might be
important for improving therapeutic efficacy of dietary recom-
mendations with a ‘personalised nutrition’ approach in MetS
patients.
Common variants in GCKR, most often the minor T-allele of the
rs780094 SNP (or rs1260326, a variant in high linkage
disequilibrium), have been reported by multiple candidate gene
and GWAS to be associated with decreased fasting glucose
[9,11,12,13,14], increased serum triglyceride [9,11,15,16] and
CRP levels [9,17,18]. However, many published claims of gene-
biomarker and gene-disease associations have not been replicated
when studied in independent populations. In this regard, the
present study replicates previous associations of the GCKR
rs1260326-P446L polymorphism with metabolic traits, including
fasting glucose, TAG and CRP levels. Moreover, diet has been
considered important in the modulation of metabolic traits related
to the MetS. In the last decade more attention has been paid to the
impact of the quality of dietary fat, independent of total amount.
Among dietary components, n-3 PUFA have been shown to confer
some cardiovascular benefits [5,6], although limited and inconsis-
tent data have been reported on the effects of n-3 PUFA on
glucose metabolism. Thus, data from the Nurses’ Health studies
suggested an increased risk of T2DM with high consumption of n-
3 PUFA [19]. These results were consistent with recent findings
from the Women’s Health Study of which higher but not lower
amounts of n-3 PUFA consumption were associated with an
increased risk of diabetes [7]. In contrast, data from other studies
like the ARIC study [20], and the Kuopio Ischemic Heart Disease
Risk factor study [21], showed no association between omega-3
fatty acids and diabetes risk. The question arises whether gene-
nutrient interactions such as GCKR and n-3 PUFA, together with
other confounding factors, might be at the root of such
inconsistencies. Our data show that subjects with the less common
T-allele and with plasma n-3 PUFA levels above the median,
showed higher plasma concentrations of fasting insulin, C-peptide
and HOMA-IR, as compared to C/C subjects, suggesting that
some individuals may be more resistant (hypo-responders) to
dietary changes than others [22,23]. Thus, general recommenda-
tions (i.e. high intake of n-3 PUFA) may not be equally benefit all
individuals.
Our study is, to our knowledge, the first to report interactions
between the GCKR locus, plasma fatty acid and glucose
metabolism in subjects with the MetS. The GCKR rs1260326-
P446L SNP interacted with plasma n-3 PUFA to influence insulin
resistance, suggesting the potential sensitivity of this SNP to dietary
factors. In contrast, no differences were observed with other types
of fatty acids in plasma such as MUFA, n-6 PUFA or SFA.
Genetic as well as functional data indicate that GCKR plays a key
role in glucose metabolism and intermediate phenotypes. Al-
though we did not perform functional studies, data from Vaxillaire
et al. suggest that the lower fasting blood glucose in the T-allele
carriers is probably due to improved hepatic glucose disposal and
insulin sensitivity; this may be due to a direct effect on the hepatic
glucose metabolism, as GCKR closely interacts with GCK in the
hepatocytes, depending on glucose concentrations, to regulate the
amount and activity of GCK and, consequently, the hepatic
glucose disposal [12]. As previously shown we observed a gene-
fatty acid interaction between the rs1260326 SNP and the levels of
n-3 PUFA in plasma. PUFAs are known regulators of hepatic gene
transcription, exerting their effects on transcription factors such as
PPARa, SREBP-1c, or HNF-4a. Fatty acid-mediated regulation
of hepatic genes by HNF-4a has been implicated in the regulation
of carbohydrate metabolism through GCK, phosphoenolpyruvate
carboxykinase and L-pyruvate kinase [24]. Thus, the decrease in
both GCK (a key enzyme of glycolysis) and G6PDH (the rate-
limiting enzyme of the pentose phosphate pathway) activities,
leading to a reduction in two key metabolites of glucose
metabolism (G6P and X5P), favors a PUFA-mediated inhibition
of ChREBP translocation. Consistent with the observation that
GCK gene expression is inhibited by PUFAs [25], recent evidence
shows that only PUFAs, but not SFA or MUFA, inhibit GCK
activity by reducing the amount of total GCK protein content.
Based on these results we may speculate that n-3 PUFA fatty acids
interact with the GCKR gene to influence insulin resistance and this
is particularly noteworthy as insulin resistance is believed to be an
important factor linking metabolic abnormalities in patients with
the MetS.
Figure 2. Predicted values for homeostasis model assessment
of insulin resistance (HOMA-IR) (A) and C-reactive protein
levels (CRP) (B) for the GCKR rs1260326-P446L polymorphism.
A difference was observed between the genotype groups, with the
minor T-allele genotype group (triangles) appearing to be ‘‘high
responders’’ to plasma concentration of omega-3 polyunsaturated fatty
acids (n-3 PUFA) and the major C allele homozygote group (circles)
appearing to be ‘‘low responders’’.
doi:10.1371/journal.pone.0020555.g002
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tion also modifies CRP levels. On the basis of the current evidence
MetS is associated with low-grade chronic inflammation charac-
terized by inflamed adipose tissue with increased macrophage
infiltration. This inflammation may link obesity and insulin
resistance. We have observed that subjects carrying the C/C
genotype and higher level of plasma n-3 PUFA had a lower grade
of inflammation as measured by serum CRP level. This novel
gene-nutrient interaction may be cautiously interpreted as a
protection against chronic inflammation associated to the MetS.
The LIPGENE cohort is a carefully characterized population, and
the multicentre origin of the patients allows extrapolation of the
results to the European population. However, LIPGENE design is
cross sectional, preventing to prove causality.
In conclusion, our results support the notion that n-3 PUFA
may play a contributing role in triggering insulin resistance and
serum levels of CRP by interacting with a genetic variant at GCKR
gene locus. Based on these data, and on the observed genotype-
dependent responses, we can infer that a recommendation to
increase n-3 PUFA could have an augmented beneficial effect on
insulin resistance and inflammatory markers only among MetS
patients carrying the C/C genotype, which might in turn have
implications with respect to cardiovascular risk.
Materials and Methods
The detailed design of the present study has been described in
the recent articles from the LIPGENE cohort [22,26,27] and
summarized below.
Ethics Statement
The study was performed in accordance with the Helsinki
Declaration of 1975 as revised in 1983, and was approved by the
local ethics committees at each centre (Research Ethics Committee
of the Adelaide and Meath Hospital and St. James’ Hospital,
Dublin, Ireland; Berkshire Local Research Ethics Committee and
University of Reading Research Ethics Committee, UK; the
Norwegian Data Inspectorate and by the Regional Committee for
Ethics in Medical Research, Oslo, Norway; Comite ´ Consultatif De
Protection Des Personnes Dans La Recherche Biome ´dicale –
MARSEILLE 1, France; the Medical Ethical Committee of
Maastricht University/University Hospital Maastricht, The Neth-
erlands; the Bioethical Committee of the Jagiellonian University,
Medical College Krakow, Poland; Regional Ethical Review Board
Uppsala, Sweden; and Comite ´E ´tico de Investigacio ´n Clı ´nica,
Hospital Universitario Reina Sofı ´a, Cordoba, Spain). All subjects
provided written informed consent before any study related
procedure. The study was registered with the US National Library
of Medicine Clinical Trials registry (NCT00429195).
Subjects
The participants, aged 35–70 years and BMI 20–40 kg/m
2,
were recruited for the LIPGENE dietary intervention study from
eight European countries (Ireland, UK, Norway, France, The
Netherlands, Spain, Poland and Sweden). Subject eligibility was
determined using a modified version of the NCEP criteria for the
MetS [28], where subjects were required to fulfil at least three of
the following five criteria: waist circumference .102 cm (men) or
.88 cm (women); fasting plasma concentration of glucose
5.5–7.0 mmol/L; TAG$1.5 mmol/L; HDL cholesterol ,1.0 mmol/L
(men) or ,1.3 mmol/L (women); and blood pressure $130/85 mmHg,
or treatment of previously diagnosed hypertension. The pre-
intervention data for these subjects were published from the
LIPGENE dietary intervention cohort elsewhere [29,30].
Anthropometric measurements were recorded according to a
standardized protocol for the LIPGENE study and blood
pressure was measured according to the guidelines of European
Society of Hypertension [31]. The present analyses include the
379 subjects with available SNP data. Of these participants,
68% received any kind of anti-hypertensive medication.
Inclusion and exclusion criteria of the LIPGENE Study are
presented in table S1.
Biochemical measurements
Plasma, serum, and buffy coat were prepared from 12 h fasting
blood samples in each subject. Serum insulin and C-peptide were
measured by solid-phase, two-site fluoroimmunometric assay on a
1235 automatic immunoassay system (AutoDELFIA kits, Wallac
Oy, Turku, Finland). Plasma glucose concentrations were
measured using the IL TestTM Glucose Hexokinase Clinical
Chemistry kit (Instrumentation Laboratories, Warrington, UK).
Homeostasis model assessment of insulin resistance (HOMA-IR)
was derived from fasting glucose and insulin levels [(fasting plasma
glucose6fasting serum insulin)/22.5] [32]. As HOMA-IR takes
into account both insulin and glucose levels, it may be a more
complete index than plasma insulin. Homeostasis model assess-
ment of b-cell function (HOMA-B) was calculated as [(206fasting
serum insulin)/(fasting plasma glucose23.5)]. Cholesterol and
triglycerides were quantified using the IL Test
TM Cholesterol kit
and IL Test
TM Triglycerides kit (Instrumentation Laboratories,
Warrington, UK).
Plasma fatty acid composition was determined as a biomarker of
habitual dietary fat intake and reflects the combination of dietary
fat consumption and endogenous de novo fatty acid biosynthesis
and metabolism. Fatty acids were extracted from plasma and
transmethylated with boron trifluoride in methanol. Fatty acid
methyl esters were analyzed by gas chromatography on a
Shimadzu GC-14A (Shimadzu, Kyoto, Japan) fitted with a
Shimadzu C-r6A integrator and a 25M BP 21 polar aluminium
silica column. Detector and injector temperatures were 260uC and
250uC respectively. Fatty acids were identified by the comparison
of the relative retention times of plasma fatty acid methyl esters
with fatty acid methyl esters standards. Fatty acid mass was
measured as a relative percentage of the total quantified fatty acids
[33]. Total plasma n-3 PUFA was calculated from the sum of
C18:3 (n-3), C18:4(n-3), C20:4 (n-3), C20:5 (n-3), C22:5 (n-3) and
C22:6 (n-3). Longchain (LC) n-3 PUFA was calculated from C20:5
(n-3) and C22:6(n-3); and n–6 PUFAs from the sum of 18:2,
18:3n–6, 20:3, 20:4n–6, and 22:4. Plasma concentrations of CRP
were determined by high-sensitivity ELISA (BioCheck, Inc., Foster
City, CA, USA) at the University College Dublin. Adiponectin was
determined by use of ELISA (DuoSetH ELISA Development
System, R&D Systems, MN, USA).
SNP Selection and Genotyping
The rs1260326-P446L polymorphism was genotyped at the
GCKR gene. DNA was extracted from buffy coat samples using the
AutoPure LS automated system (Gentra Systems Inc., Minneap-
olis, MN, USA), and low yielding samples (,10 ng) were subjected
to whole genome amplification using the REPLI-g kit (Qiagen Ltd.
West Sussex, UK). Genotyping was conducted by Progenika
Biopharma SA (Derio, Spain). Adherence to Hardy-Weinberg
equilibrium (HWE) at each SNP locus was determined using the
x2 test with 1 degree of freedom.
Statistical analysis
Biochemical variables were assessed for normality of distribu-
tion, and skewed variables were normalised by log10 or square
GCKR Interacts with Omega 3 and Insulin Resistance
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carried out using SPSS version 18.0 for Windows (SPSS Inc,
Chicago, IL). Data are presented as means 6 standard error for
continuous variables and as frequencies or percentages for
categorical variables. Comparisons of frequencies between qual-
itative variables were carried out using the Chi-squared test.
Potential confounding factors were age, sex, BMI, anti-hyperten-
sion pharmacological treatment and LIPGENE centre of origin.
ANOVA-based models were used to test for associations between
individual SNP and the variables studied, with the SNP as fixed
factor, and age, BMI, sex and centre of origin as covariates. The
effect of each SNP interacting with groups of plasma fatty acids
(omega-3 and omega-6 polyunsaturated, saturated, monounsatu-
rated) on each biochemical variable was investigated using the
median of plasma fatty acids to dichotomize the population, and
using the resulting groups (above-the-median versus below-the-
median) as a fixed factor in combination with the SNP genotypes
in an univariate ANOVA analysis with the same covariates and
Bonferroni corrections as exposed above. Thus, in this model we
could assess the associated effects of SNP alone, fatty acids alone
and the interaction between the SNP and the fatty acids on the
selected variables. Bonferroni’s test was used in all cases where
post-hoc was necessary.
Supporting Information
Table S1 Inclusion and exclusion criteria of the LIPGENE
Study.
(DOC)
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